Publications by authors named "Nisha Nanda"

Claim this Profile
A
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.
Robert C Doebele, Lara E Davis, Aria Vaishnavi, Anh T Le, Adriana Estrada-Bernal, Nisha Nanda

Cancer Discov· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.
Jorge E Cortes, Franck E Nicolini, Meir Wetzler, Jeffrey H Lipton, Luke Akard, Nisha Nanda

Clin Lymphoma Myeloma Leuk· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors.
John Nemunaitis, Alain Mita, Joe Stephenson, Monica M Mita, John Sarantopoulos, Nisha Nanda

Cancer Chemother Pharmacol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.
Jorge Cortes, Jeff H Lipton, Delphine Rea, Raghunadharao Digumarti, Charles Chuah, Nisha Nanda

Blood· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Critical role for Syk in responses to vascular injury.
Patrick Andre, Toshifumi Morooka, Derek Sim, Keith Abe, Clifford Lowell, Nisha Nanda

Blood· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model.
Michael P Reilly, Uma Sinha, Pierrette André, Scott M Taylor, Yvonne Pak, Nisha Nanda

Blood· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel targets for antithrombotic drug discovery.
Nisha Nanda, David R Phillips

Blood Cells Mol Dis· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platelet aggregation induces platelet aggregate stability via SLAM family receptor signaling.
Nisha Nanda, Patrick Andre, Ming Bao, Karl Clauser, Francis Deguzman

Blood· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contact-induced activation.
Nisha Nanda, Ming Bao, Hanna Lin, Karl Clauser, Laszlo Komuves

J Biol Chem· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases.
Craig D C Bailey, Robert M Graham, Nisha Nanda, Peter J A Davies, Gail V W Johnson

Mol Cell Neurosci· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct transglutaminase 2-independent and transglutaminase 2-dependent pathways mediate articular chondrocyte hypertrophy.
Kristen A Johnson, Deborah van Etten, Nisha Nanda, Robert M Graham, Robert A Terkeltaub

J Biol Chem· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis